Latest news and press releases about Galectin Therapeutics Inc. (GALT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer.
Price
| Price | $3.68 |
| Market Cap | $242M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -1.79 |
| EV / EBITDA | -16.28 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 24.44% |
| Return on Invested Capital | -174.29% |
| Return on Assets | -157.87% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALT · AURA · DMAC · DRTS · DSGN · ENGN · IMAB
Explore sector: Healthcare · Biotechnology
More sections of GALT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks